#USA #Philadelphia #SYN-001 #Synaptiq Therapeutics #22q11DS

Introduction

On July 23, 2026, Synaptiq Therapeutics made its official debut, following the acquisition of the SYN-001 program originally owned by Nobias Therapeutics. This privately held clinical-stage biotechnology firm aims to spearhead advancements in treatment for neuropsychiatric symptoms linked to 22q11.2 Deletion Syndrome (22q11DS).

The Formation of Synaptiq Therapeutics

Founded by a consortium of investors from both Europe and the United States, including the Investcorp-backed Sanos Group and Icelandic funds from AxUM Securities, Synaptiq aims to pool resources and expertise for a focused push towards drug development. The company has appointed Patrick Dougherty as the Chief Executive Officer who emphasizes that this venture represents a significant milestone in the journey of SYN-001.

SYN-001 and its Significance

SYN-001 has been recognized as a promising candidate for the treatment of various symptoms associated with 22q11DS, a genetic disorder that affects approximately one in every 2,000 to 3,300 live births worldwide. The complexity and frequency of symptoms such as anxiety, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorders present a pressing need for effective therapies, particularly as existing treatment options are limited.

The program has already yielded encouraging results from earlier Phase II trials which showed a favorable safety profile along with statistically significant improvements in subgroups of patients. As SYN-001 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, the upcoming Phase IIb trial will incorporate specific assessments tailored to 22q11DS, enabling a focused evaluation of its efficacy.

Pioneering Drug Development

Synaptiq Therapeutics is strategically based in Iceland but will utilize a well-established drug development platform led by Arctic Therapeutics. The collaboration promises to merge extensive clinical operations with scientific expertise and a groundbreaking partnership with the Center for Applied Genomics at the Children's Hospital of Philadelphia. These combined efforts will facilitate the initiation of the Phase IIb clinical trial across prominent medical centers throughout North America and Europe, further establishing SYN-001 as a potential first-line treatment for 22q11DS-related symptoms.

The Importance of the Quest

The creation of Synaptiq Therapeutics is seen as a turning point not only for the company but also for the countless children and families affected by 22q11DS. Chief Executive Officer Dougherty reflects on how the experiences of these individuals and their families significantly motivate the drive for innovation in treatment options.

Future Prospects

With a strong foundation built on experience and commitment, Synaptiq Therapeutics is set to accelerate the development of SYN-001. The company invites stakeholders and the broader community to witness the unfolding journey towards potentially transforming the therapeutic landscape for individuals grappling with 22q11DS.

Conclusion

As Synaptiq Therapeutics embarks on this critical mission, it stands at the forefront of rare disease research, eagerly anticipating regulatory approval to offer meaningful solutions for those impacted by neuropsychiatric symptoms related to 22q11DS. The hopeful outlook prevalent among its leadership symbolizes a brighter future for treatment in this underserved patient population.